From: Ceftazidime and cefepime antagonize 5-fluorouracil’s effect in colon cancer cells
A) HCT-116 | 0 | 5-FU (8 μM) | |||
48 h | 72 h | 48 h | 72 h | ||
0 | Pre G1 | 4.2 ± 0.7 | 4.0 ± 0.4 | 16.9 ± 2.5(a) | 36.7 ± 11.7(a) |
G0/G1 | 55.9 ± 4.5 | 62.7 ± 2.0 | 48.4 ± 2.3(a) | 39.0 ± 9.5(a) | |
S | 11.4 ± 1.7 | 6.6 ± 1.6 | 10.6 ± 1.0 | 6.6 ± 0.7 | |
G2/M | 23.4 ± 2.5 | 21.0 ± 1.4 | 22.3 ± 2.9 | 16.4 ± 2.4(a) | |
CFP 50 μg/ml | Pre G1 | 4.9 ± 1.6 | 9.3 ± 2.9(a) | 12.6 ± 1.6(a,b,c)(↓) | 23.2 ± 5.3(a,c) |
G0/G1 | 51.7 ± 2.8 | 53.8 ± 3.6(a) | 53.9 ± 3.9 | 51.4 ± 4.1(a) | |
S | 13.6 ± 1.6 | 7.4 ± 1.4 | 9.7 ± 0.9(c) | 6.4 ± 0.6 | |
G2/M | 24.6 ± 0.9 | 23.6 ± 2.2(a) | 22.5 ± 2.9 | 17.5 ± 2.3(a,c) | |
CFT 100 μg/ml | Pre G1 | 6.4 ± 2.3(a) | 9.8 ± 0.9(a) | 8.9 ± 1.6(a,b)(↓) | 35.6 ± 6.4(a,c) |
G0/G1 | 53.3 ± 1.7 | 56.9 ± 1.3(a) | 53.6 ± 3.3(b)(↑) | 41.6 ± 2.6(a,c) | |
S | 12.8 ± 2.9 | 6.6 ± 1.0 | 10.8 ± 1.0 | 8.0 ± 0.7(b)(↑) | |
G2/M | 24.4 ± 1.2 | 24.3 ± 0.5(a) | 25.7 ± 5.3 | 14.3 ± 4.3(a,c) | |
B) DLD-1 | 0 | 5-FU (16 μM) | |||
48 h | 72 h | 48 h | 72 h | ||
0 | Pre G1 | 3.2 ± 1.6 | 3.8 ± 1.1 | 6.3 ± 2.3 | 4.7 ± 0.3 |
G0/G1 | 53.4 ± 2.5 | 68.0 ± 2.0 | 49.3 ± 4.4 | 69.4 ± 5.0 | |
S | 16.4 ± 2.6 | 8.6 ± 0.9 | 32.0 ± 6.1(a) | 20.1 ± 2.9(a) | |
G2/M | 22.4 ± 2.4 | 19.1 ± 1.9 | 10.3 ± 1.7(a) | 5.4 ± 2.7(a) | |
CFP 50 μg/ml | Pre G1 | 2.6 ± 0.3 | 9.5 ± 4.1(a) | 4.0 ± 1.2(c) | 13.6 ± 1.3(a,b)(↑) |
G0/G1 | 48.8 ± 4.0 | 59.6 ± 3.6(a) | 51.4 ± 9.0 | 64.6 ± 3.7 | |
S | 29.2 ± 8.1 | 13.1 ± 3.3(a) | 31.7 ± 5.3 | 17.6 ± 1.2(a) | |
G2/M | 18.4 ± 4.3 | 17.0 ± 3.5 | 12.8 ± 5.0 | 4.3 ± 2.7(a,c) | |
CFT 100 μg/ml | Pre G1 | 9.3 ± 2.5(a) | 40.6 ± 5.2(a) | 7.1 ± 1.5 | 21.0 ± 6.0(a,b,c)(↑) |
G0/G1 | 52.6 ± 3.3 | 38.2 ± 4.3(a) | 40.4 ± 3.0(a,b,c)(↓) | 54.6 ± 7.1(a,b,c)(↓) | |
S | 14.6 ± 3.2 | 8.4 ± 0.6 | 30.3 ± 7.5(a,c) | 10.1 ± 1.3(b)(↓) | |
G2/M | 15.7 ± 2.8(a) | 12.0 ± 1.6(a) | 18.2 ± 3.2(b)(↑) | 13.7 ± 1.0(a,b)(↑) |